Note: Ingredients listed on restricted chemical lists
EC/CAS
108-95-2
Name of the chemical
Phenol
Concentration
N/A
EC/CAS
7732-18-5
Name of the chemical
Water, distilled, conductivity or of similar purity H2O
Concentration
N/A
General Information
Revision date
2015-06-10
Product name
Octreotide Acetate Injection
Manufacturer Name
Fresenius Kabi USA, LLC
Icons in SDS
Company Information
company name
Fresenius Kabi USA, LLC
GHS Information
Signal word
DANGER
Section 2
Signal word
DANGER. GHS Class: Respiratory sensitisation. Category 1. Skin Sensitization. Category 1.
Hazard statements
May cause allergy or asthma symptoms or breathing difficulties if inhaled. May cause an allergic skin reaction.
Precautionary statements
Avoid breathing dust/fume/gas/mist/vapours/spray. Contaminated work clothing should not be allowed out of the workplace. Wear protective gloves/protective clothing/eye protection/face protection. In case of inadequate ventilation wear respiratory protection. IF ON SKIN: Wash with plenty of water. IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing. Specific treatment (see ... on this label). If skin irritation or rash occurs: Get medical advice/attention. If experiencing respiratory symptoms: Call a POISON CENTER or doctor/physician. Take off contaminated clothing and wash it before reuse. Dispose of contents/container in accordance with Local, State, Federal and Provincial regulations. Emergency Overview: This product is intended for therapeutic use only when prescribed by a physician. Potential adverse reactions from prescribed doses and overdoses are described in the package insert.
Principle Routes of Exposure
Inhalation Ingestion Eye contact Skin Absorption. Injection.
Potential health effects
Eye: Contact with eyes may cause irritation. Signs/Symptoms: Adverse reactions from therapeutic doses include: Gallbladder abnormalities (stones and/or biliary sludge), sinus bradycardia, conduction abnormalities, diarrhea, loose stools, hypoglycemia, hyperglycemia, hypothyroidism, pain of injection, headache, and dizziness. No frank overdose has occurred in any patient to date. Occupational exposure has not been fully investigated. Aggravation of Pre-Existing Individuals who are sensitive to octreotide or any of the components. Conditions: Octreotide Acetate Signs/Symptoms: There are no indications that octreotide acetate has potential for drug abuse or dependence. Octreotide acetate levels in the central nervous system are negligible even after doses up to 30,000 mcg.
